Direct-acting antivirals (DAAs) have significantly improved the treatment response in HCV chronic infection with higher potency and better tolerance. We established the prevalence of naturally occurring NS5A and NS5B inhibitor resistance-associated mutations (RAMs) in HCV genotype (GT)-1 chronically infected individuals in Ireland.
Methods
In a multicentre cohort study, employing sequencing-based analysis, the presence of RAMs was determined in the HCV NS5A (n=119) and the NS5B (n=60).
Results
Naturally occurring RAMs in NS5A (M28V, R30Q, L31I, P58S, E62D and Y93H) were identified in 14.3% (17/119) of cases. Notably, the major RAM Y93H was found in 15.2% (7/46) of GT-1b versus none (0/73) in GT-1a (P=0.0009). The frequency of Y93H present in IFNL3 rs12979860 CC major homozygotes (30%, 3/10) was higher than in the non-CC group (11.1%, 4/36). GT-1b-infected individuals harbouring Y93H had significantly higher viral loads than those without this mutation (P=0.006). Additionally, two novel insertions in GT-1a and GT-1b were identified in the NS5A interferon sensitivity-determining region. In NS5B, only minor pre-existing RAMs (L159F, C316N and I434M) were detected in 10% (6/60) of samples. The proportion of individuals harbouring multiple RAMs in different DAA target regions was low.
Conclusions
RAMs to novel DAAs were infrequent in the DAA-naive population in the present study. The NS5A Y93H substitution was the only significant RAM identified. Given the low frequency of multiple RAMs in NS3, NS5A and NS5B regions and the unclear impact of preexisting Y93H on the response in combination therapies, the role of pre-treatment RAM analysis in treatment-naive individuals requires further investigation.
References
1.
SchinaziR., HalfonP., MarcellinP., AsselahT.HCV direct-acting antiviral agents: the best interferon-free combinations.Liver Int2014; 34Suppl 1: 69–78.
2.
GogelaN.A., LinM.V., WisockyJ.L., ChungR.T.Enhancing our understanding of current therapies for hepatitis C virus (HCV).Curr HIV/AIDS Rep2015; 12: 68–78.
3.
CollisonM., ChinJ.L., Abu ShanabA.Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-alpha and ribavirin in chronic hepatitis C virus genotype 1 infection.J Interferon Cytokine Res2015; 35: 126–133.
4.
NguyenL.T., GrayE., DeanJ.Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals.Antivir Ther2015; 20: 865–869.
5.
PaolucciS., FiorinaL., MarianiB.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients.Virol J2013; 10: 355.
6.
BartelsD.J., SullivanJ.C., ZhangE.Z.Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.J Virol2013; 87: 1544–1553.
7.
GaoM., NettlesR.E., BelemaM.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature2010; 465: 96–100.
8.
KrishnanP., BeyerJ., MistryN.In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.Antimicrob Agents Chemother2015; 59: 979–987.
9.
SunJ.H., O'BoyleD.R.II, ZhangY.Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.Hepatology2012; 55: 1692–1699.
10.
Peres-da-SilvaA., de AlmeidaA.J., LampeE.NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.J Antimicrob Chemother2015; 70: 726–730.
11.
PlazaZ., SorianoV., VispoE.Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.Antivir Ther2012; 17: 921–926.
12.
KanT., HashimotoS., KawabeN.The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.J Gastroenterol2016; 51: 63–70.
13.
Aissa LarousseJ., TrimouletP., Recordon PinsonP.Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia.Virol J2015; 12: 84.
14.
ItakuraJ., KurosakiM., TakadaH.Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy.Hepatol Res2015; 45: E115–E121.
15.
KrishnanP., TripathiR., SchnellG.Resistance analysis of baseline and treatment-emergent variants in the AVIATOR Study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1.Antimicrob Agents Chemother2015; 59: 5445–5454.
16.
PeifferK.H., SommerL., SusserS.IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients.Hepatology2016; 63: 63–73.
17.
EnomotoN., SakumaI., AsahinaY.Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.N Engl J Med1996; 334: 77–81.
18.
PascuM., MartusP., HohneM.Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.Gut2004; 53: 1345–1351.
19.
KohashiT., MaekawaS., SakamotoN.Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication.J Viral Hepat2006; 13: 582–590.
20.
IkedaM., YiM., LiK., LemonS.M.Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.J Virol2002; 76: 2997–3006.
21.
Torres-PuenteM., CuevasJ.M., Jimenez-HernandezN.Contribution of insertions and deletions to the variability of hepatitis C virus populations.J Gen Virol2007; 88: 2198–2203.
22.
SchneiderM.D., SarrazinC.Antiviral therapy of hepatitis C in 2014: do we need resistance testing?Antiviral Res2014; 105: 64–71.
23.
PovedaE., WylesD.L., MenaA., PedreiraJ.D., Castro-IglesiasA., CachayE.Update on hepatitis C virus resistance to direct-acting antiviral agents.Antiviral Res2014; 108: 181–191.
24.
DonaldsonE.F., HarringtonP.R., O'RearJ.J., NaegerL.K.Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.Hepatology2015; 61: 56–65.
25.
TongX., Le PogamS., LiL.In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.J Infect Dis2014; 209: 668–675.
26.
KinugasaH., IkedaF., TakaguchiK.Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype 1 infection.Antivir Ther2016; 21: 37–44.
27.
KarinoY., ToyotaJ., IkedaK.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.J Hepatol2013; 58: 646–654.
28.
FridellR.A., WangC., SunJ.H.Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Hepatology2011; 54: 1924–1935.
29.
WangC., SunJ.H., O'BoyleD.R.IIPersistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Antimicrob Agents Chemother2013; 57: 2054–2065.
30.
FridellR.A., QiuD., WangC., ValeraL., GaoM.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob Agents Chemother2010; 54: 3641–3650.
31.
LawitzE.J., GruenerD., HillJ.M.A Phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.J Hepatol2012; 57: 24–31.
32.
BilelloJ.P., LallosL.B., McCarvilleJ.F.In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Antimicrob Agents Chemother2014; 58: 4431–4442.
33.
LamA.M., EspirituC., BansalS.Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.Antimicrob Agents Chemother2012; 56: 3359–3368.
